As previously described, the initial CML-related hematological alterations in the p210BCR/ABL transgenic mouse strain used in our studies started to be easily detectable at about 6 months of age and then quickly progressed during the ensuing 2–4 months (7–9 months of age) until culminating into the full-blown disease and the eventual death of the diseased animals. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.